Vernakalant is an investigational candidate used for the treatment of atrial fibrillation.
As per the terms of the agreement, effectiveness of the agreement triggers an initial payment of $60 million to Cardiome from Merck.
Cardiome Pharma is engaged in the development and commercialisation of novel treatments for disorders of the heart and circulatory system.